Supernus Pharmaceuticals | SUPN - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Abbott USD 2.25B 73M 2025-12
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
Aurora Cannabis CAD -35.79M 19.88M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Cara Therapeutics USD -2.39M 3.49M 2025-03
Corcept Therapeutics USD 4.49M 5.73M 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Pacira USD 3.19M 9.96M 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Xeris Pharmaceuticals USD 16.77M 10.04M 2025-12